Caplin Point Laboratories Limited (BOM:524742)
India · Delayed Price · Currency is INR 2,520.55
+39.95 (1.61%)
At close: Aug 17, 2026
Caplin Point Laboratories Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 22,873 | 21,872 | 19,375 | 16,941 | 14,667 | 12,694 |
Other Revenue | - | - | 21 | 20.1 | 15.9 | 15.4 |
| 22,873 | 21,872 | 19,396 | 16,961 | 14,683 | 12,710 | |
Revenue Growth | 15.02% | 12.77% | 14.35% | 15.51% | 15.53% | 19.64% |
Cost of Revenue | 9,156 | 8,657 | 8,017 | 7,561 | 6,792 | 5,724 |
Gross Profit | 13,717 | 13,215 | 11,379 | 9,400 | 7,891 | 6,986 |
Selling, General & Admin | 2,101 | 1,992 | 1,779 | 1,437 | 1,371 | 1,154 |
Research & Development | - | - | 766.8 | 737.2 | 631.9 | 592.7 |
Other Operating Expenses | 3,650 | 3,615 | 2,305 | 1,683 | 1,456 | 1,275 |
Operating Expenses | 6,532 | 6,334 | 5,509 | 4,391 | 3,908 | 3,489 |
Operating Income | 7,185 | 6,881 | 5,870 | 5,009 | 3,984 | 3,496 |
Interest Expense | -8.7 | -8.7 | -6.1 | -7.8 | -7.8 | -7 |
Interest & Investment Income | - | - | 636.4 | 472.8 | 354.1 | 235 |
Earnings From Equity Investments | - | 0.4 | -0.1 | 2.7 | 0.8 | - |
Currency Exchange Gain (Loss) | - | - | 207.8 | 113.1 | 138.2 | 109.8 |
Other Non Operating Income (Expenses) | 1,260 | 1,155 | 97.2 | 60.7 | 48.2 | 23 |
EBT Excluding Unusual Items | 8,436 | 8,028 | 6,805 | 5,651 | 4,517 | 3,857 |
Gain (Loss) on Sale of Assets | - | - | -37.6 | -6.5 | -3.6 | 1.2 |
Pretax Income | 8,436 | 8,028 | 6,768 | 5,644 | 4,514 | 3,858 |
Income Tax Expense | 1,655 | 1,531 | 1,357 | 1,030 | 743.6 | 773.7 |
Earnings From Continuing Operations | 6,781 | 6,497 | 5,411 | 4,614 | 3,770 | 3,085 |
Minority Interest in Earnings | -127.1 | -84.9 | -47.8 | -43.3 | -7.3 | -86.1 |
Net Income | 6,654 | 6,412 | 5,363 | 4,571 | 3,763 | 2,998 |
Net Income to Common | 6,654 | 6,412 | 5,363 | 4,571 | 3,763 | 2,998 |
Net Income Growth | 17.73% | 19.56% | 17.33% | 21.48% | 25.49% | 23.76% |
Shares Outstanding (Basic) | 76 | 76 | 76 | 76 | 76 | 76 |
Shares Outstanding (Diluted) | 76 | 76 | 76 | 76 | 77 | 76 |
Shares Change | -0.14% | -0.14% | 0.05% | -0.26% | 0.18% | 0.07% |
EPS (Basic) | 87.53 | 84.36 | 70.57 | 60.19 | 49.62 | 39.61 |
EPS (Diluted) | 87.29 | 84.11 | 70.25 | 59.90 | 49.18 | 39.26 |
EPS Growth | 17.90% | 19.73% | 17.28% | 21.80% | 25.27% | 23.81% |
Free Cash Flow | - | 2,751 | 2,409 | 1,726 | 779 | 2,456 |
Free Cash Flow Per Share | - | 36.08 | 31.55 | 22.61 | 10.18 | 32.15 |
Dividend Per Share | - | 8.000 | 6.000 | 5.000 | 4.500 | 4.000 |
Dividend Growth | - | 33.33% | 20.00% | 11.11% | 12.50% | 33.33% |
Gross Margin | 59.97% | 60.42% | 58.67% | 55.42% | 53.74% | 54.96% |
Operating Margin | 31.41% | 31.46% | 30.26% | 29.53% | 27.13% | 27.51% |
Profit Margin | 29.09% | 29.32% | 27.65% | 26.95% | 25.62% | 23.59% |
Free Cash Flow Margin | - | 12.58% | 12.42% | 10.17% | 5.30% | 19.32% |
EBITDA | 7,940 | 7,609 | 6,487 | 5,507 | 4,399 | 3,939 |
EBITDA Margin | 34.71% | 34.79% | 33.44% | 32.46% | 29.96% | 30.99% |
D&A For EBITDA | 755.53 | 727.7 | 616.4 | 497.2 | 415.8 | 442.3 |
EBIT | 7,185 | 6,881 | 5,870 | 5,009 | 3,984 | 3,496 |
EBIT Margin | 31.41% | 31.46% | 30.26% | 29.53% | 27.13% | 27.51% |
Effective Tax Rate | 19.62% | 19.07% | 20.05% | 18.25% | 16.48% | 20.05% |
Revenue as Reported | 24,133 | 23,027 | 20,339 | 17,610 | 15,227 | 13,082 |